199 related articles for article (PubMed ID: 22396451)
1. Wild-type tumor repressor protein 53 (Trp53) promotes ovarian cancer cell survival.
Mullany LK; Liu Z; King ER; Wong KK; Richards JS
Endocrinology; 2012 Apr; 153(4):1638-48. PubMed ID: 22396451
[TBL] [Abstract][Full Text] [Related]
2. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo.
Mullany LK; Fan HY; Liu Z; White LD; Marshall A; Gunaratne P; Anderson ML; Creighton CJ; Xin L; Deavers M; Wong KK; Richards JS
Oncogene; 2011 Aug; 30(32):3522-36. PubMed ID: 21423204
[TBL] [Abstract][Full Text] [Related]
3. Tumor repressor protein 53 and steroid hormones provide a new paradigm for ovarian cancer metastases.
Mullany LK; Liu Z; Wong KK; Deneke V; Ren YA; Herron A; Richards JS
Mol Endocrinol; 2014 Jan; 28(1):127-37. PubMed ID: 24264574
[TBL] [Abstract][Full Text] [Related]
4. Mutant p53 Promotes Epithelial Ovarian Cancer by Regulating Tumor Differentiation, Metastasis, and Responsiveness to Steroid Hormones.
Ren YA; Mullany LK; Liu Z; Herron AJ; Wong KK; Richards JS
Cancer Res; 2016 Apr; 76(8):2206-18. PubMed ID: 26964623
[TBL] [Abstract][Full Text] [Related]
5. SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice.
Ogawa S; Fukuda A; Matsumoto Y; Hanyu Y; Sono M; Fukunaga Y; Masuda T; Araki O; Nagao M; Yoshikawa T; Goto N; Hiramatsu Y; Tsuda M; Maruno T; Nakanishi Y; Hussein MS; Tsuruyama T; Takaori K; Uemoto S; Seno H
Gastroenterology; 2020 Aug; 159(2):682-696.e13. PubMed ID: 32360551
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of TRP53, PTEN, RB1, and/or CDH1 in the ovarian surface epithelium induces ovarian cancer transformation and metastasis.
Shi M; Whorton AE; Sekulovski N; Paquet M; MacLean JA; Song Y; Van Dyke T; Hayashi K
Biol Reprod; 2020 Apr; 102(5):1055-1064. PubMed ID: 31930396
[TBL] [Abstract][Full Text] [Related]
7. Global deletion of Trp53 reverts ovarian tumor phenotype of the germ cell-deficient white spotting variant (Wv) mice.
Cai KQ; Wang Y; Smith ER; Smedberg JL; Yang DH; Yang WL; Xu XX
Neoplasia; 2015 Jan; 17(1):89-100. PubMed ID: 25622902
[TBL] [Abstract][Full Text] [Related]
8. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
[TBL] [Abstract][Full Text] [Related]
9. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
10. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
[TBL] [Abstract][Full Text] [Related]
11. Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer.
Wu R; Baker SJ; Hu TC; Norman KM; Fearon ER; Cho KR
Am J Pathol; 2013 Apr; 182(4):1391-9. PubMed ID: 23499052
[TBL] [Abstract][Full Text] [Related]
12. Cell type-specific targeted mutations of Kras and Pten document proliferation arrest in granulosa cells versus oncogenic insult to ovarian surface epithelial cells.
Fan HY; Liu Z; Paquet M; Wang J; Lydon JP; DeMayo FJ; Richards JS
Cancer Res; 2009 Aug; 69(16):6463-72. PubMed ID: 19679546
[TBL] [Abstract][Full Text] [Related]
13. Functional analysis of miR-34c as a putative tumor suppressor in high-grade serous ovarian cancer.
Yu Z; Kim J; He L; Creighton CJ; Gunaratne PH; Hawkins SM; Matzuk MM
Biol Reprod; 2014 Nov; 91(5):113. PubMed ID: 25273528
[TBL] [Abstract][Full Text] [Related]
14. Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival.
Mullany LK; Wong KK; Marciano DC; Katsonis P; King-Crane ER; Ren YA; Lichtarge O; Richards JS
Neoplasia; 2015 Oct; 17(10):789-803. PubMed ID: 26585234
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer.
Couto SS; Cao M; Duarte PC; Banach-Petrosky W; Wang S; Romanienko P; Wu H; Cardiff RD; Abate-Shen C; Cunha GR
Differentiation; 2009 Jan; 77(1):103-11. PubMed ID: 19281769
[TBL] [Abstract][Full Text] [Related]
16. Trp53 null and R270H mutant alleles have comparable effects in regulating invasion, metastasis, and gene expression in mouse colon tumorigenesis.
Tang J; Feng Y; Kuick R; Green M; Green M; Sakamoto N; Kurosu Y; Lin J; Cho KR; Fearon ER
Lab Invest; 2019 Oct; 99(10):1454-1469. PubMed ID: 31148594
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma.
Walton J; Blagih J; Ennis D; Leung E; Dowson S; Farquharson M; Tookman LA; Orange C; Athineos D; Mason S; Stevenson D; Blyth K; Strathdee D; Balkwill FR; Vousden K; Lockley M; McNeish IA
Cancer Res; 2016 Oct; 76(20):6118-6129. PubMed ID: 27530326
[TBL] [Abstract][Full Text] [Related]
18. Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses.
Timofeev O; Klimovich B; Schneikert J; Wanzel M; Pavlakis E; Noll J; Mutlu S; Elmshäuser S; Nist A; Mernberger M; Lamp B; Wenig U; Brobeil A; Gattenlöhner S; Köhler K; Stiewe T
EMBO J; 2019 Oct; 38(20):e102096. PubMed ID: 31483066
[TBL] [Abstract][Full Text] [Related]
19. Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.
Zanjirband M; Edmondson RJ; Lunec J
Oncotarget; 2016 Jun; 7(26):40115-40134. PubMed ID: 27223080
[TBL] [Abstract][Full Text] [Related]
20. Interaction of the oncogenic miR-21 microRNA and the p53 tumor suppressor pathway.
Ma X; Choudhury SN; Hua X; Dai Z; Li Y
Carcinogenesis; 2013 Jun; 34(6):1216-23. PubMed ID: 23385064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
